ESR1 and triple-negative breast carcinoma: Subtype distribution was as follows: ER + /HER2-, n = 113 (73%); HER2 + (either ER + or ER-), n = 25 (16%); ER and PR-negative/HER2-negative (triple-negative breast cancer, TNBC), n = 17 (11%).